Life sciences regulatory compliance in 2020: Taking a holistic view
Life sciences companies are responsible for helping to improve the lives of millions of individuals and are necessarily held to a high standard of public trust. With such high stakes, regulators have made it clear that "paper compliance" is not enough and that companies are expected to maintain a comprehensive, real-time view of their compliance programs’ effectiveness.
The theme for the 2020 life sciences regulatory outlook is for companies to take a broader view of compliance so that these activities are part of a company's overall business strategy. With compliance top of mind for all involved when a new product nears launch, a new system is brought online, or a new business relationship is explored, companies can be better equipped to do more than comply with life sciences regulations. Active compliance can also be a force to support the needs of your teams, and the process and technological tools they use, to be better integrated and aligned in your company's mission.
Read the full article in Deloitte website